BR112015000798A2 - heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3 - Google Patents

heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3

Info

Publication number
BR112015000798A2
BR112015000798A2 BR112015000798A BR112015000798A BR112015000798A2 BR 112015000798 A2 BR112015000798 A2 BR 112015000798A2 BR 112015000798 A BR112015000798 A BR 112015000798A BR 112015000798 A BR112015000798 A BR 112015000798A BR 112015000798 A2 BR112015000798 A2 BR 112015000798A2
Authority
BR
Brazil
Prior art keywords
polypeptide
cell
carrier
construct
polypeptide construct
Prior art date
Application number
BR112015000798A
Other languages
English (en)
Inventor
Yiu Kon Ng Gordon
E Weisser Nina
Bhimarao Dixit Surjit
Spreter Von Kreudenstein Thomas
Original Assignee
Zymeworks Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymeworks Inc filed Critical Zymeworks Inc
Publication of BR112015000798A2 publication Critical patent/BR112015000798A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

resumo heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3 são divulgados neste documento construtos de heteromultímero multiespecífico compreendendo construtos de heteromultímero multiespecífico compreendendo: um primeiro construto de polipeptídeo compreendendo um primeiro polipeptídeo de cadeia pesada e um construto de polipeptídeo de ligação cd3 que se liga a um complexo de cd3 pelo menos uma célula expressando cd3; um segundo construto de polipeptídeo compreendendo um segundo polipeptídeo de cadeia pesada, que é diferente do referido primeiro polipeptídeo de cadeia pesada e um construto de polipeptídeo de ligação ao antígeno que se liga a um antígeno alvo de pelo menos uma célula b; em que: o referido construto de heteromultímero multiespecífico engata simultaneamente pelo menos uma referida célula b e pelo menos uma referida célula expressando cd3, de modoque a célula expressando cd3 seja ativada, assim, induzindo a morte da célula b; e os referidos primeiro e segundo polipeptídeos de cadeia pesada formam uma região de fc heterodimérica compreendendo uma região de imunoglobulina variante ch3 compreendendo pelo menos uma mutação de aminoácido que promove a formação da referida fc heterodimérica com estabilidade ao menos comparável a uma fc homodimérica nativa e com elevado grau de pureza. também são fornecidos construtos de heteromultímero multiespecífico isolado compreendendo: um primeiro construto de polipeptídeo compreendendo um primeiro polipeptídeo transportador, fundido com o construto de polipeptídeo de pelo menos uma ligação de cd3 que se liga a um complexo de cd3 pelo menos uma célula expressando cd3; um segundo construto de polipeptídeo compreendendo um segundo polipeptídeo transportador, que é diferente do referido primeiro polipeptídeo transportador, fundido com o construto de polipeptídeo de pelo menos uma ligação de antígeno que se liga a um antígeno alvo em pelo menos uma célula b; em que os referidos primeiro e o segundo polipeptídeos transportadores são derivados de uma proteína por segmentação da referida proteína, cada polipeptídeo transportador compreende uma sequência de aminoácidos pelo menos 90% idêntica a um segmento da referida proteína, e em que os referidos polipeptídeos transportadores se juntam para formar uma estrutura quase nativa da referida proteína monomérica.
BR112015000798A 2012-07-13 2013-07-13 heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3 BR112015000798A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261671640P 2012-07-13 2012-07-13
US201361845948P 2013-07-12 2013-07-12
PCT/US2013/050411 WO2014012085A2 (en) 2012-07-13 2013-07-13 Bispecific asymmetric heterodimers comprising anti-cd3 constructs

Publications (1)

Publication Number Publication Date
BR112015000798A2 true BR112015000798A2 (pt) 2017-06-27

Family

ID=49916711

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015000798A BR112015000798A2 (pt) 2012-07-13 2013-07-13 heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3

Country Status (11)

Country Link
US (3) US20140154253A1 (pt)
EP (1) EP2872170A4 (pt)
JP (1) JP2015528003A (pt)
KR (1) KR20150036606A (pt)
CN (1) CN104640562A (pt)
AU (1) AU2013289883B2 (pt)
BR (1) BR112015000798A2 (pt)
CA (1) CA2878843A1 (pt)
HK (1) HK1207575A1 (pt)
RU (1) RU2650868C2 (pt)
WO (1) WO2014012085A2 (pt)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2417156E (pt) 2009-04-07 2015-04-29 Roche Glycart Ag Anticorpos trivalentes, biespecíficos
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US20120302737A1 (en) 2009-09-16 2012-11-29 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
DK3029066T3 (da) 2010-07-29 2019-05-20 Xencor Inc Antistoffer med modificerede isoelektriske punkter
BR112013001847A2 (pt) 2010-08-24 2016-05-31 Hoffmann La Roche anticorpo biespecífico, método de preparação do anticorpo biespecífico, do anticorpo biespecífico trivalente, métodos e composição farmacêutica
DK2635607T3 (da) 2010-11-05 2019-11-18 Zymeworks Inc Stabilt heterodimert antistofdesign med mutationer i fc-domænet
WO2012116926A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Antigen binding proteins
KR101572338B1 (ko) 2011-02-28 2015-11-26 에프. 호프만-라 로슈 아게 1가 항원 결합 단백질
WO2012116453A1 (en) 2011-03-03 2012-09-07 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
US20140161800A1 (en) 2011-04-22 2014-06-12 John W. Blankenship Prostate-Specific Membrane Antigen Binding Proteins and Related Compositions and Methods
CN103842383B (zh) 2011-05-16 2017-11-03 健能隆医药技术（上海）有限公司 多特异性fab融合蛋白及其使用方法
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
ES2899956T3 (es) 2011-11-04 2022-03-15 Zymeworks Inc Diseño de anticuerpo heterodimérico estable con mutaciones en el dominio Fc
US9499634B2 (en) 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
AU2013289881B2 (en) 2012-07-13 2018-01-18 Zymeworks Bc Inc. Multivalent heteromultimer scaffold design and constructs
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
EP2914634B1 (en) * 2012-11-02 2017-12-06 Zymeworks Inc. Crystal structures of heterodimeric fc domains
CA2892059C (en) * 2012-11-21 2023-02-14 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
EP2943511B1 (en) 2013-01-14 2019-08-07 Xencor, Inc. Novel heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
CA2906927C (en) 2013-03-15 2021-07-13 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
BR112016000666A2 (pt) * 2013-07-12 2017-10-03 Zymeworks Inc Constructos de ligação de antígeno cd3 e cd19 biespecíficos
PT3406633T (pt) 2013-07-25 2022-05-04 Cytomx Therapeutics Inc Anticorpos multi-específicos, anticorpos ativáveis multi-específicos e métodos de utilização dos mesmos
CA2922912A1 (en) 2013-10-11 2015-04-16 F. Hoffmann-La Roche Ag Multispecific domain exchanged common variable light chain antibodies
WO2015073721A1 (en) * 2013-11-13 2015-05-21 Zymeworks Inc. Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof
CN106062206A (zh) * 2014-01-15 2016-10-26 酵活有限公司 双特异性cd3和cd19抗原结合构建体
TWI701042B (zh) * 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
MX2016012578A (es) 2014-03-28 2017-04-13 Xencor Inc Anticuerpos biespecificos que se unen a cd38 y cd3.
WO2015153765A1 (en) 2014-04-01 2015-10-08 Adimab, Llc Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
CA2946503C (en) 2014-05-28 2022-11-22 Zymeworks Inc. Modified antigen binding polypeptide constructs and uses thereof
US9212225B1 (en) * 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
US9611325B2 (en) * 2014-07-21 2017-04-04 Wuhan Yzy Biopharma Co., Ltd. Construction and application of bispecific antibody HER2xCD3
CN107108738A (zh) 2014-07-25 2017-08-29 西托姆克斯治疗公司 抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法
BR112017005988A2 (pt) * 2014-09-26 2017-12-19 Macrogenics Inc diacorpo de fc monovalente biespecífico cd19 x cd3 capaz de realizar ligação específica a cd19 e a cd3, complexo polipeptídico covalentemente associado, composição farmacêutica, e uso da composição farmacêutica
RS60739B1 (sr) 2014-11-17 2020-09-30 Regeneron Pharma Postupci za lečenje tumora upotrebom cd3xcd20 bispecifičnog antitela
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EA037065B1 (ru) 2014-11-26 2021-02-01 Ксенкор, Инк. Гетеродимерные антитела, связывающие cd3 и cd38
LT3223845T (lt) 2014-11-26 2021-08-25 Xencor, Inc. Heterodimeriniai antikūnai, kurie suriša cd3 ir cd20
ES2764111T3 (es) * 2014-12-03 2020-06-02 Hoffmann La Roche Anticuerpos multiespecíficos
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
US10556952B2 (en) 2015-03-30 2020-02-11 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to Fc gamma receptors
AU2016257721B2 (en) 2015-05-01 2019-11-14 The Regents Of The University Of California Glycan-dependent immunotherapeutic molecules
WO2016180969A1 (en) * 2015-05-13 2016-11-17 Ablynx N.V. T cell recruiting polypeptides based on tcr alpha/beta reactivity
CA2985700C (en) * 2015-05-13 2022-06-28 Ablynx N.V. T cell recruiting polypeptides based on cd3 reactivity
CN114652827A (zh) 2015-05-29 2022-06-24 安普希韦纳治疗公司 双特异性cd33和cd3结合蛋白质的使用方法
EP3310811B1 (en) * 2015-06-16 2021-06-16 Genentech, Inc. Anti-cd3 antibodies and methods of use
CN104892765B (zh) * 2015-06-29 2018-04-10 深圳市国创纳米抗体技术有限公司 一种抗CD3抗原和Her‑2抗原的双特异性抗体
EP3322735A4 (en) * 2015-07-15 2019-03-13 Zymeworks Inc. BISPECIFIC ANTIGEN-BINDING CONSTRUCTS CONJUGATED TO A MEDICINAL PRODUCT
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) * 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
EP3341021A4 (en) * 2015-08-27 2019-03-13 Celldex Therapeutics, Inc. ANTI-ALK ANTIBODIES AND METHOD OF USE THEREOF
MY197562A (en) 2015-09-21 2023-06-23 Aptevo Res & Development Llc Cd3 binding polypeptides
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
WO2017055314A1 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
KR20180085800A (ko) 2015-12-07 2018-07-27 젠코어 인코포레이티드 Cd3 및 psma에 결합하는 이종이합체성 항체
CN106883297B (zh) 2015-12-16 2019-12-13 苏州康宁杰瑞生物科技有限公司 基于ch3结构域的异二聚体分子、其制备方法及用途
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
RS62841B1 (sr) 2016-02-03 2022-02-28 Amgen Res Munich Gmbh Bcma i cd3 konstrukti antitela koji angažuju bispecifične t ćelije
MX2018009804A (es) * 2016-02-12 2018-11-09 Nantomics Llc Identificacion de gran alcance de neoepitopos especificos para pacientes como objetivos terapeuticos para inmunoterapias de cancer.
CA3017776A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
US20190111079A1 (en) * 2016-04-15 2019-04-18 Zymeworks Inc. Multi-specific antigen-binding constructs targeting immunotherapeutics
EA201892693A1 (ru) 2016-05-20 2019-04-30 Харпун Терапьютикс, Инк. Белки, содержащие одноцепочечный вариабельный фрагмент, связывающийся с cd3
AU2017285218A1 (en) 2016-06-14 2018-12-06 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
CN106117358A (zh) * 2016-06-16 2016-11-16 中山大学 抗cd3单域抗体
EP4050032A1 (en) 2016-06-28 2022-08-31 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
US20190241878A1 (en) * 2016-07-01 2019-08-08 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US20190218290A1 (en) * 2016-09-07 2019-07-18 Anti-Doping Lab Qatar Camel derived polypeptides binding human cd3, identified using a novel one-step method
SG11201903302UA (en) 2016-10-14 2019-05-30 Xencor Inc Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
RU2769871C2 (ru) * 2016-12-13 2022-04-07 Делиниа, Инк. Поливалентные модуляторы регуляторных t-клеток
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
SG11201907299XA (en) 2017-02-08 2019-09-27 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
US20200002436A1 (en) * 2017-02-20 2020-01-02 Dragonfly Therapeutics, Inc. Proteins binding cd123, nkg2d and cd16
WO2018152518A1 (en) 2017-02-20 2018-08-23 Adimab, Llc Proteins binding her2, nkg2d and cd16
JOP20190222A1 (ar) 2017-04-11 2019-09-24 Zymeworks Inc الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3
KR20200005732A (ko) 2017-04-11 2020-01-16 인히브릭스, 인크. 제한된 ｃｄ3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 이를 이용한 방법
WO2018199593A1 (ko) * 2017-04-24 2018-11-01 재단법인 목암생명과학연구소 Her3 및 cd3에 결합하는 이중특이적 항체
AU2018271930A1 (en) * 2017-05-23 2019-12-12 Dragonfly Therapeutics, Inc. A protein binding NKG2D, CD16 and a tumor-associated antigen
CN110719920B (zh) * 2017-06-14 2024-01-30 苏州丁孚靶点生物技术有限公司 蛋白质异二聚体及其用途
CA3068056A1 (en) * 2017-06-22 2018-12-27 Development Center For Biotechnology Asymmetric heterodimeric fc-scfv fusion anti-globo h and anti-cd3 bispecifc antibody and uses thereof in cancer therapy
MA49517A (fr) 2017-06-30 2020-05-06 Xencor Inc Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène
AR112603A1 (es) 2017-07-10 2019-11-20 Lilly Co Eli Anticuerpos biespecíficos inhibidores de punto de control
CN111315767A (zh) 2017-08-22 2020-06-19 萨纳生物有限责任公司 可溶性干扰素受体及其用途
AU2018347607A1 (en) 2017-10-14 2020-03-26 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
CN112272563A (zh) 2017-11-08 2021-01-26 Xencor股份有限公司 使用新颖抗pd-1序列的双特异性和单特异性抗体
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN107903324B (zh) * 2017-11-15 2021-01-29 北京绿竹生物技术股份有限公司 一种结合人cd19和cd3的双特异性抗体
MA51291A (fr) 2017-12-19 2020-10-28 Xencor Inc Protéines de fusion il-2 fc modifiées
CN108129566B (zh) * 2017-12-31 2021-05-11 中国科学院武汉病毒研究所 靶向间皮素的c-型单域抗体及其制备方法与应用
CN112368012A (zh) 2018-02-08 2021-02-12 蜻蜓疗法股份有限公司 靶向nkg2d受体的抗体可变结构域
MX2020008289A (es) 2018-02-08 2020-09-25 Genentech Inc Moleculas biespecificas de union al antigeno y metodos de uso.
TW202000238A (zh) * 2018-02-26 2020-01-01 比利時商艾伯林克斯公司 編碼肽連接子之經改良核苷酸序列
AU2019227715B2 (en) 2018-02-28 2022-03-31 Ap Biosciences, Inc. Bifunctional proteins combining checkpoint blockade for targeted therapy
CN110218255B (zh) * 2018-03-02 2020-12-04 广西医科大学 抗CD3的纳米抗体CD3/Nb47及其制备方法与应用
CA3096052A1 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
CN112867734A (zh) 2018-04-18 2021-05-28 Xencor股份有限公司 包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途
JP2021520829A (ja) 2018-04-18 2021-08-26 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質
WO2019237081A1 (en) * 2018-06-07 2019-12-12 Cullinan Management, Inc. Multi-specific binding proteins and methods of use thereof
US20210277118A1 (en) * 2018-06-21 2021-09-09 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
CN112771077A (zh) 2018-08-31 2021-05-07 瑞泽恩制药公司 针对cd3/c20双特异性抗体的减轻细胞因子释放综合征的给药策略
AU2019346466A1 (en) 2018-09-25 2021-05-20 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
CA3115096A1 (en) 2018-10-03 2020-04-09 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
JP2022512629A (ja) * 2018-10-23 2022-02-07 マジェンタ セラピューティクス インコーポレイテッド Ｆｃサイレンス化抗体薬物コンジュゲート（ＡＤＣ）及びその使用
TW202033218A (zh) * 2018-12-07 2020-09-16 大陸商江蘇恆瑞醫藥股份有限公司 多特異性蛋白分子
WO2020132810A1 (en) * 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
JP7261307B2 (ja) * 2019-01-28 2023-04-19 ウーシー バイオロジクス アイルランド リミテッド 新規二重特異性ｃｄ３／ｃｄ２０ポリペプチド複合体
US11472890B2 (en) 2019-03-01 2022-10-18 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
CN112390882A (zh) * 2019-08-19 2021-02-23 杨洋 靶向cd3和cd20的双特异性抗体及其应用
CN110551222B (zh) * 2019-08-27 2023-06-06 重庆市畜牧科学院 一种新型双功能抗体及其用途
MX2022007158A (es) 2019-12-13 2022-07-11 Genentech Inc Anticuerpos anti-ly6g6d y metodos de uso.
EP4045541A4 (en) 2019-12-20 2023-08-16 Shandong Boan Biotechnology Co., Ltd. ANTI-CD3 ARM OPTIMIZED IN THE GENERATION OF B-SPECIFIC ANTIBODIES TO T LYMPHOCYTES FOR IMMUNOTHERAPY
TW202140553A (zh) 2020-01-13 2021-11-01 美商威特拉公司 C5ar1抗體分子及其用途
CA3181963A1 (en) * 2020-05-04 2021-11-11 Immunorizon Ltd. Precursor tri-specific antibody constructs and methods of use thereof
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
MX2022016069A (es) 2020-06-19 2023-02-02 Hoffmann La Roche Anticuerpos que se unen a cd3 y cd19.
EP4200332A1 (en) 2020-08-19 2023-06-28 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
TW202237654A (zh) * 2020-12-09 2022-10-01 美商詹努克斯治療有限公司 與經腫瘤活化之靶定psma及效應細胞抗原之抗體相關之組合物及方法
AU2022207985A1 (en) 2021-01-13 2023-07-06 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
EP4032910A1 (en) * 2021-01-22 2022-07-27 ETH Zurich Bispecific binding agent that binds to cd3 and a fluorophore
KR20230156079A (ko) 2021-03-09 2023-11-13 젠코어 인코포레이티드 Cd3과 cldn6에 결합하는 이종이량체 항체
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6129914A (en) * 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) * 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
EP1820513A1 (en) * 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
DK2235064T3 (en) * 2008-01-07 2016-01-11 Amgen Inc A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
ES2500066T3 (es) * 2008-01-25 2014-09-30 Amgen, Inc Anticuerpos frente a ferroportina y métodos de uso
EP3375790A1 (en) * 2008-10-01 2018-09-19 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
US20120100140A1 (en) * 2009-01-23 2012-04-26 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
CN103124743A (zh) * 2009-12-29 2013-05-29 新兴产品开发西雅图有限公司 Ron结合构建物及其使用方法
CA2796633C (en) * 2010-04-23 2020-10-27 Genentech, Inc. Production of heteromultimeric proteins
DK2635607T3 (da) * 2010-11-05 2019-11-18 Zymeworks Inc Stabilt heterodimert antistofdesign med mutationer i fc-domænet
ES2899956T3 (es) * 2011-11-04 2022-03-15 Zymeworks Inc Diseño de anticuerpo heterodimérico estable con mutaciones en el dominio Fc
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES

Also Published As

Publication number Publication date
AU2013289883A1 (en) 2015-02-19
WO2014012085A9 (en) 2015-03-19
RU2015102193A (ru) 2016-08-27
EP2872170A4 (en) 2016-06-22
JP2015528003A (ja) 2015-09-24
US20190248897A1 (en) 2019-08-15
CA2878843A1 (en) 2014-01-16
EP2872170A2 (en) 2015-05-20
WO2014012085A2 (en) 2014-01-16
KR20150036606A (ko) 2015-04-07
CN104640562A (zh) 2015-05-20
HK1207575A1 (en) 2016-02-05
US20140154253A1 (en) 2014-06-05
US20210317212A1 (en) 2021-10-14
RU2650868C2 (ru) 2018-04-17
WO2014012085A3 (en) 2014-03-27
AU2013289883B2 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
BR112015000798A2 (pt) heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3
CY1122216T1 (el) Νεες ετεροδιμερικες πρωτεϊνες
AR111361A1 (es) Anticuerpos biespecíficos de unión específica a pd1 y lag3
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
PE20200384A1 (es) Metodo de fabricacion de anticuerpos bispecificos, anticuerpos bispecificos y uso terapeutico de dichos anticuerpos
GT201700162A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
AR085404A1 (es) Proteinas de union a antigeno
PE20181066A1 (es) Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos
EA201691925A1 (ru) Биспецифические антитела, которые связываются с cd38 и cd3
BR112014001573B8 (pt) Molécula fv ao antígeno multivalente
BR112016014810A2 (pt) Antagonistas de fcrn e métodos de uso
PE20210844A1 (es) Contorsbodies 2 + biespecificos
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
EA201791057A1 (ru) Антигенсвязывающие молекулы, содержащие тримерный лиганд семейства tnf
BR112017013981A2 (pt) receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
EA201591407A1 (ru) Антитела, содержащие химерные константные домены
AR077088A1 (es) Proteinas biespecificas de union a antigeno
EA201692476A1 (ru) Модифицированные антигенсвязывающие полипептидные конструкции и их применение
UA117575C2 (uk) Антитіло, яке специфічно зв'язується з il-17a та його застосування
PE20211291A1 (es) Anticuerpos anti-ox40 y metodos de uso
EA201400568A1 (ru) Альбуминсвязывающие антитела и их связывающие фрагменты
DOP2019000011A (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20150023A1 (es) Proteinas de union a antigeno st2
AR077111A1 (es) Proteinas biespecificas tetravalentes de union a antigeno

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements